Stewart Catherine E, Moseley Merrick J, Georgiou Pantelis, Fielder Alistair R
Division of Optometry & Visual Science, City, University of London, United Kingdom.
Division of Optometry & Visual Science, City, University of London, United Kingdom.
J AAPOS. 2017 Oct;21(5):402-406. doi: 10.1016/j.jaapos.2017.06.018. Epub 2017 Sep 7.
Occlusion therapy remains the mainstay treatment of amblyopia, but its outcome is not assured or universally excellent. Many factors are known to influence treatment outcome, among which compliance is foremost. The occlusion dose monitor (ODM) removes one variable from the treatment equation, because it records the occlusion actually received by-rather than prescribed for-the child. Improvement observed can thus be quantitatively related to the patching received. This review summarizes the insights the ODM has provided to date particularly in elucidating the dose-response relationship. We are entering the era of personalized ophthalmology in which treatments will be tailored to the needs of the individual child and facilitated by the use of wearable monitors.
遮盖疗法仍然是弱视的主要治疗方法，但其效果并不确定，也并非普遍良好。已知许多因素会影响治疗效果，其中依从性最为重要。遮盖剂量监测器（ODM）消除了治疗方案中的一个变量，因为它记录的是儿童实际接受的遮盖时间，而不是规定的遮盖时间。因此，观察到的改善情况可以与接受的遮盖治疗量进行定量关联。本综述总结了ODM迄今为止所提供的见解，尤其是在阐明剂量反应关系方面。我们正在进入个性化眼科时代，在这个时代，治疗将根据每个孩子的需求进行定制，并借助可穿戴监测器来实现。
